Health experts have revealed that the new drug-resistant tuberculosis shows promise however it should be approached with caution. The Community Research Advisors Group (CRAG) argue that research into bedaquiline - a new drug fast tracked for multidrug-resistant tuberculosis (MDR-TB) - should proceed cautiously in people with drug-sensitive tuberculosis and they urged researchers to balance the goal of shortening treatment for drug-sensitive TB with patient safety. Current treatments for drug-resistant tuberculosis show improved outcomes when continued for 18 to 24 months and even then cure rates range from 11 percent to 79 percent depending on the extent of resistance. This presents